Narrow Results

Psoriasis is a chronic inflammatory cutaneous disease characterized by clinical manifestations of erythema and white scales. The pathogenesis of psoriasis is not yet clear. Despite a combination of hormonal therapy and physiotherapy used in Western medicine, the condition often relapses after withdrawal of drugs. Traditional Chinese medicine (TCM) has therapeutic features and may be a clinically effective formula by regulating unbalanced immune systems, such as by targeting interleukins. In this paper, we review recent research about how Chinese medicine immunoregulates psoriasis via interleukins, and systematically summarizes the related mechanisms. There are three common pathways leading to psoriasis: (1) Th17 cells secrete IL-17, which is stimulated by IL-23; (2) Th1 cells secrete IL-21, TNF-$\alpha$ and IFN-$\gamma$, with the help of Th17 cells; (3) Th22 cells secrete IL-22 under the stimulation of Th17 cells. Clinical and experiment data indicate that TCM could modify psoriasis by antagonizing or regulating interleukin and IL-23/IL-17 axis to inhibit the main pathways.

Schisandra sphenanthera Rehd. et Wils (S. sphenanthera) is a single species of Schisandra genus, Magnoliaceae family, and it is a famous medicinal herb mostly growing in southern China, China Taiwan and Vietnam. S. sphenanthera is usually used for the treatments of hepatitis, Alzheimer’s disease, renal transplantation, osteoporosis, and insomnia. In present studies, approximately 310 natural constituents have been isolated from S. sphenanthera, including lignans, triterpenes, volatile oils, and polysaccharides, which were mainly obtained from the fruits and stems of S. sphenanthera. Pharmocological studies have shown that the extracts and monomeric compounds of S. sphenanthera possessed wide-range bioactivities, such as antitumor, anti-oxidant, anti-inflammatory, osteoblastic, immune regulation, neuroprotective, kidney protection, hepatoprotective, and antiviral activities. However, resource availability, quality control measures, in-depth in vivo pharmacological study, and clinical application are still insufficient and deserve further studies. This review systematically summarized literatures on the botany, phytochemistry, pharmacology, development utilization, and clinical application of S. sphenanthera, in hopes of provide a useful reference for researchers for further studies of this plant.

Sinomenium acutum is the dry stem of Sinomenium acutum (Thunb.) Rehd et Wils. (S. acutum) and Sinomenium acutum (Thunb.) Rehd. et Wils. var. cinereum Rehd. et Wils and is mainly distributed in China and Japan. As a traditional Chinese medicine (TCM) for dispelling wind and dampness in China, it is widely distributed and has a long history of drug use. In recent years, with the increase of the incidence of rheumatoid disease, S. acutum has become the focus of research. This paper reviews the literature on the chemical constituents, pharmacological effects, clinical applications and pharmacokinetics and safety of S. acutum from the past 60 years. At present, more than 210 natural compounds have been isolated from S. acutum, including alkaloids, lignans, triterpenoid saponins, steroids, and other structures. Pharmacological activities of S. acutum were mainly reported on anti-inflammatory, analgesic, anti-allergic, immunosuppressive, anti-tumor, liver-protective, anti-oxidative, and other effects, and clinical applications were mainly recorded on rheumatoid arthritis, ankylosing spondylitis, and other diseases. The clinical use of SIN has fewer side effects and more safety; only a small number of gastrointestinal reactions occurred, and the symptoms disappeared after the drug stopped. The purpose of this paper is to lay a foundation and provide reference for the follow-up research and wide application of S. acutum.

Ganoderma is the dried fruiting bodiy of Ganoderma lucidum (Leyss.ex Fr.) Karst. or Ganoderma sinense Zhao, Xu et Zhang, belonging to the family Polyporaceae, which grows mainly in tropical, subtropical, and temperate regions. As a traditional Chinese medicine, Ganoderma has been used in China for more than 2000 years because of its medicinal properties, such as relieving cough and asthma, providing nourishment, and strengthening. Currently, more than 470 natural compounds have been obtained from the fungus, mainly including terpenoids, steroids, alkaloids, phenols, and other types of compounds. Modern pharmacological studies have shown that Ganoderma has antitumor, anti-inflammatory, hypoglycemic, hypolipidemic, and immunomodulatory effects. It is mainly used in clinical practice for the treatment of Diabetic Nephropathy and malignant tumors, with few side effects and high safety. This paper reviews the progress of research on its chemical composition, pharmacological effects, and clinical applications, with the goal of providing a basis for the better development and utilization of Ganoderma.

Traditional Chinese Medicine (TCM) has achieved high clinical efficacy in treating malignancies in recent years and is thus gradually becoming an important therapy for patients with advanced tumor for its benefits in reducing side effects and improving patients’ immune status. However, it has not been internationally recognized for cancer treatment because TCM’s anti-tumor mechanism is not fully elucidated, limiting its clinical application and international promotion. This review traced the mechanism of the TCM-mediated tumor cell death pathway and its effect on remodeling the tumor immune microenvironment, its direct impact on the microenvironment, its anti-tumor effect in combination with immunotherapy, and the current status of clinical application of TCM on tumor treatment. TCM can induce tumor cell death in many regulatory cell death (RCD) pathways, including apoptosis, autophagy, pyroptosis, necroptosis, and ferroptosis. In addition, TCM-induced cell death could increase the immune cells’ infiltration with an anti-tumor effect in the tumor tissue and elevate the proportion of these cells in the spleen or peripheral blood, enhancing the anti-tumor capacity of the tumor-bearing host. Moreover, TCM can directly affect immune function by increasing the population or activating the sub-type immune cells with an anti-tumor role. It was concluded that TCM could induce a pan-tumor death modality, remodeling the local TIME differently. It can also improve the systemic immune status of tumor-bearing hosts. This review aims to establish a theoretical basis for the clinical application of TCM in tumor treatment and to provide a reference for TCM’s potential in combination with immunotherapy in cancer treatment.

Taxus, a rare and protected genus predominantly distributed across the Northern Hemisphere’s temperate regions, has garnered global attention due to its significant potential in medical research and pharmaceutical development, bolstered by advancements in cultivation techniques and medical technology. This review primarily focuses on the chemical constituents and pharmacological activities of Taxus, underscoring the progress and potential of these components in clinical applications. Recent studies have revealed that Taxus contains not only taxane active components but also flavonoids and polysaccharides with distinct activities. These compounds from Taxus exhibit potent antitumor, anti-inflammatory, immunomodulatory, antibacterial, and antidiabetic properties with evident mechanisms of action. Notably, the representative compound, paclitaxel, has demonstrated significant efficacy in treating various cancers, such as ovarian, breast, and lung cancer. This paper also reviews the basic situation of Taxus drug formulations, with extracts primarily administered orally and monomeric taxanes typically via injection, reflecting a mature development stage with ongoing research into oral formulations. Finally, this review summarizes the pharmacokinetic characteristics of crucial compounds in Taxus, including their absorption, distribution, metabolism, and excretion patterns in the human body. These pharmacokinetic profiles provide crucial guidance for evaluating the overall dosing regimen of Taxus and its components. The paper concludes with a forward-looking analysis of the potential applications of these compounds in disease treatment, envisioning their role in the future of medical and pharmaceutical advancements.

The following topics are under this section:

• The future of predicting lifestyle diseases is here in Asia
• Breaking Barriers for Artificial Intelligence (AI) in Healthcare: bridging vision and reality with the language of trust
• Overcoming Challenges of Managing Information in Life Sciences, Towards the Digital Future
• Under the Weather: Cybersecurity Woes in the healthcare Industry

Photodynamic therapy (PDT) has received increased attention since the regulatory approvals of several photosensitizers and light applicators in numerous countries and regions around the world. In recent years, much progress has been seen in basic research as well as clinical application. PDT clinical application has now extended from treating malignant diseases to nonmalignant diseases. This review article will present recent clinical data published in English journals. The data will be organized according to their clinical specialties. The new development and future direction in clinical applications of PDT for the management of both malignant and nonmalignant diseases will be discussed.

Premature ovarian failure (POF) is a heterogeneous disorder characterized by amenorrhea, infertility, lack of estrogen, and elevated gonadotropin levels before the age of 40. Most POF females have fertility problems due to defects of germ cell development or complete ovarian failure. Though hormonal therapy could partially restore ovarian function, effects of these treatments are transient, much less for regeneration and repair of the ovaries. With the rise of regenerative medicine, stem cells transplantation gives new hope for repairing POF related ovaries damage. Studies from animal models indicate that stem cell transplantation can, at least in part, repair ovarian structure, improve ovarian function and fertility in POF, i.e., the bone marrow mesenchymal stem cells (BMSCs) and umbilical cord mesenchymal stem cells (UC-MSCs) can differentiate to ovaries and facilitate fertility recovery. However, the underlying mechanisms remain unclear, which limits their clinical applications. Here, we discuss the recent progress on the clinical applications of stem cells for POF treatment, which would become promising therapies for POF patients.

Thin endometrium (TE) is a heterogeneous uterine disorder characterized by TE that results in infecundity. Patients with TE are usually associated with menstrual abnormalities and suffer from pelvic pain. A number of treatments have been employed to promote endometrial growth, but none has been validated effective. With the development of stem cell therapy, better means for TE treatment to improve endometrium, thus restoring its function become possible. Studies in TE mouse models have shown that stem cell implantation could improve pregnancy. However, the efficiency is relatively low and the safety for its clinical applications remains unclear. Here, we summarize recent progresses on the clinical application of stem cells for TE treatment, which would provide valuable references for stem cell therapy in TE patients.

Boron Neutron Capture Therapy (BNCT) is one of the most promising treatments among NCTs due to its long-term clinical application and unequivocal success in clinical trials. Nevertheless, current clinically used boronophenylalanine suffers from large uptake dose and low blood-to-tumor selectivity, and that initiated an overwhelming screening of next-generation BNCT drugs. Various boron agents, such as small molecules and macro/nano-vehicles, have been explored to greater success. In this chapter, different types of agents are rationally analyzed and compared, and the feasible targets are shared to present a perspective for the future of BNCT in cancer treatment.